ArticleThrombosis journal2025
Therapeutic targets for venous thromboemblism: proteome-wide mendelian randomization and colocalization analyses.
Article in Thrombosis journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVenous thromboembolism (VTE) is a significant global health issue, yet effective therapeutic targets for its prevention and treatment remain elusive. This study aimed to identify plasma proteins causally associated with VTE risk using proteome-wide Mendelian randomization (MR) and colocalization analyses.
methodsWe utilized genome-wide association study (GWAS) data from the UK Biobank and FinnGen cohorts, encompassing 38,573 VTE cases and 946,373 controls. Plasma protein levels were quantified using Olink technology in the UK Biobank Pharma Proteomics Project (UKB-PPP) and SomaScan in the deCODE Health study. MR analysis was performed to assess causal relationships, followed by colocalization analysis to evaluate shared genetic variants. Functional enrichment analyses and molecular docking were conducted to explore biological mechanisms and predict potential therapeutic compounds.
resultsEight proteins showed significant associations with VTE risk after Bonferroni correction (p < 3.19 × 10
conclusionsThis study highlights novel therapeutic targets for VTE and provides insights into potential drug candidates. These findings offer a foundation for future research and drug development aimed at reducing VTE risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.